SAVA: Cassava Pharma Analyst Consensus Forecast
The market trend for Cassava Sciences, Inc. (SAVA) shown on this price chart reflects the dynamics of a company focused on developing Alzheimer's disease therapies in the US, where business success depends on the test results of its lead drug candidate. The technology stack relies on IT protein modeling and laboratory analysis automation, with the current metric standing at 7.99. Meanwhile, participant loyalty in Simufilam clinical trials faces risks due to regulatory probes regarding data integrity.
Analytical breakdowns for Cassava (SAVA)
- price and consensus price forecast:
- market capitalization information:
- balance sheet equity data:
- business debt structure and liquidity details:
Debt to Equity Ratio Cassava Sciences, Inc.|SAVA - Long-Term Debt to Capital|Current Liabilities to Capital Cassava Pharma|SAVA - Company Total Debt|Debts to Book Capitalization Cassava|SAVA - Company Long-Term Debt|Company Short-Term Loans and Borrowings Cassava Sciences|Immediate Liquidity cassavasciences.com
- financial results and valuation multiples details:
SAVA - Net Profit|Future Profit Cassava Sciences, Inc.|SAVA - P/E Multiple|Forward P/E Multiple Cassava Sciences Inc|SAVA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Cassava|SAVA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Cassava Sciences|SAVA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth cassavasciences.com|SAVA - Net earnings per share growth this year|Net earnings per share growth forecast for next year Cassava Sciences, Inc.
Summary company analytics:SAVA cassavasciences.com
This indicator synthesizes collective expert assessments into a single fair value vector, neutralizing short-term volatility to identify the long-term fundamental trend. The price action of the average expected price from investment banks reflects a revaluation of Cassava Sciences, Inc. (SAVA) assets, accounting for geopolitical risks that restrict Alzheimer's drug clinical trials to the US domestic market.
Competitors of Cassava Sciences, Inc.
Analyst Median Target biogen.com|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Analyst Consensus Forecast Regencell Bioscience Ltd RGC|AXSM: Consensus Target|ACAD: Price Target Chart|XENE: Analyst Consensus Forecast|vikingtherapeutics.com (VKTX) - Analyst Consensus Forecast|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|PRTA (Prothena Corporation PLC) - Analyst Consensus Forecast|Consensus Target Alector Therapeutics (ALEC)|Analyst Consensus Forecast ANNX|Analyst Consensus Forecast omeros.com (OMER)|Price Target Chart Neurogene Corp NGNE|Analyst Median Target AC Immune Inc (ACIU)|VYGR - Price Target Chart|Analyst Median Target neumoratx.com NMRA|SCLX: Analyst Consensus Forecast|Tevogen Bio Holdings Inc. (TVGN) - Analyst Consensus Forecast|Consensus Target ACOG|Price Target Chart CGTX|Analyst Consensus Forecast IKT|Analyst Consensus Forecast assertiotx.com (ASRT)|Coya Therapeutics - Consensus Target|Fair Value Consensus VTGN|OVID - Price Target Chart|Analyst Median Target Acumen Pharmaceuticals, Inc ABOS|CRVO: Analyst Consensus Forecast|Consensus Target Alterity Therapeutics Limited|CLNN (Clene Inc) - Analyst Consensus Forecast|PepGen Corp (PEPG) - Analyst Median Target|Analyst Consensus Forecast JUNS|RLMD - Average Forecast Price|Price Target Chart Annovis Bio, Inc. ANVS|GRCE: Broker Consensus Forecast|Firefly Neuroscience - Analyst Consensus Forecast|Klotho Neurosciences Inc (KLTO) - Consensus Target|NRSN: Analyst Consensus Forecast|Average Forecast Price Reviva Pharmaceuticals, Inc. (RVPH)|Price Target Chart MetaVia Inc.|neuraxis.com (NRXS) - Analyst Median Target|Consensus Target HSDT (Helius Medical)|PASG (passagebio.com) - Fair Value Consensus|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|Analyst Median Target Minerva (NERV)|ATHA - Price Target Chart|ADXN (addextherapeutics.com) - Broker Consensus Forecast|ALZN: Analyst Consensus Forecast|Consensus Target Cyclerion Therapeutics, Inc.|Consensus Target PTIX|Pasithea (KTTA) - Analyst Median Target|Price Target Chart Cortigent, Inc. (CRGT)|Analyst Median Target avenuetx.com|Analyst Consensus Forecast BCLI (BrainStorm Cell Therapeutics)|Analyst Consensus Forecast Cara Therapeutics Inc. CARA|CHRO: Consensus Target|ELYM: Price Target Chart|ITCI: Analyst Consensus Forecast|longboardpharma.com (LBPH) - Analyst Consensus Forecast|Price Target Chart Marinus Pharmaceuticals, Inc.|Broker Consensus Forecast NKGN (NKGen Biotech Inc)|Analyst Consensus Forecast NRBO|SAGE - Average Forecast Price|Synaptogenix, Inc. - Consensus Target|Analyst Consensus Forecast trevena.com TRVN|VIGL - Price Target Chart|Fair Value Consensus WENA (Anew Medical Inc.)|Cerevel (CERE) - Price Target Chart
